| Stereochemistry | ABSOLUTE |
| Molecular Formula | C33H38N2O8 |
| Molecular Weight | 590.6634 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C(NC5=C4C=CC(OC)=C5)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)\C=C\C6=CC(OC)=C(O)C=C6
InChI
InChIKey=MMUMZMIKZXSFSD-ADSVITMPSA-N
InChI=1S/C33H38N2O8/c1-39-20-7-8-21-22-11-12-35-17-19-14-28(43-29(37)10-6-18-5-9-26(36)27(13-18)40-2)32(41-3)30(33(38)42-4)23(19)16-25(35)31(22)34-24(21)15-20/h5-10,13,15,19,23,25,28,30,32,34,36H,11-12,14,16-17H2,1-4H3/b10-6+/t19-,23+,25-,28-,30+,32+/m1/s1
Rescimetol (CD-3400) developed by Nippon Chemiphar Co. Ltd., is an antihypertensive agent belonging to the class of rauwolfa alkaloids. CD-3400 was shown to have low toxicity and a weak central action. CD-3400 possessing a sustained antihypertensive activity may be prescribed in cases when long-term therapy is required for hypertensive patients.
CNS Activity
Originator
Approval Year
PubMed
Patents
Sample Use Guides
4-16 mg/kg p.o in rats
Rescimetol (CD-3400), 5 mg/kg/day p.o. for 14 days, produced 25 to 30 mmHg fall in systolic blood pressure during the administrations, and blood pressure was returned to the pretreatment level within 5 days following withdrawal of the agent. The higher dose of CD-3400, 12 mg/ kg/day p.o., caused a more marked fall in systolic blood pressure by 40 to 50 mmHg during repeated administrations and the pressure returned to the pretreatment level more than 9 days following the withdrawal of the agent.
Route of Administration:
Oral
ACTIVE MOIETY
